⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27480377 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL5932392 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL726184 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL5932906 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL79864 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL8366297 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL5932095 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL9339993 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL10437286 | 0.97 | EPHX1 (0.70) | — | |
| SCHEMBL42438 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939327-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-26 | — | — | US | claimed |
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | claimed |
| EP-3693360-B1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-13 | — | — | EP | claimed |
| EP-3693368-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-06 | — | — | EP | claimed |
| EP-3816153-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2023-10-18 | — | — | EP | claimed |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-07 | — | — | US | claimed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | claimed |
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | claimed |
| EP-1787991-B2 | PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-24 | — | — | EP | claimed |
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | claimed |
| WO-1998038156-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-03 | — | — | WO | claimed |
| WO-1998034935-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-08-13 | — | — | WO | claimed |
| WO-1998033758-A1 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-06 | — | — | WO | claimed |
| WO-1997014417-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-04-24 | — | — | WO | claimed |
| EP-0648771-A1 | Galanthamine derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-04-19 | — | — | EP | claimed |
| US-5112998-A | Intermediates for vitamin D3 | KURARAY CO., LTD. (JP) | 1992-05-12 | — | — | US | claimed |
| EP-0374781-A2 | Novel coupler for photography | KONICA CORPORATION (JP) | 1990-06-27 | — | — | EP | claimed |
| EP-0000640-B1 | TETRAHYDRO-S-TRIAZINE THIONES, PROCESS FOR THEIR PREPARATION AND ACARICIDAL COMPOSITIONS CONTAINING THEM. | Pfizer Limited (GB) | 1981-06-03 | — | — | EP | claimed |
| US-4250090-A | COLORFASTNESS; WETFASTNESS; ACID AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | claimed |
| EP-0000640-A1 | Tetrahydro-s-triazine thiones, process for their preparation and acaricidal compositions containing them. | Pfizer Limited (GB) | 1979-02-07 | — | — | EP | claimed |